VXF

Vanguard Extended Market ETF

The meeting with the FDA is scheduled for January 2026.

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash.

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively.

Serina noted that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.

The firm announced positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers, with 15 of 64 patients in the trial surviving for more than 21 months.

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei said.

The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.